Mucopolysaccharidosis III type IIIA Sanfilippo's syndrome type A
Conditions
Interventions
Investigational Product, Dose, and Mode of Administration:
HGT-1410 at a dose of 45 mg administered every 2 weeks (Q2W) or 45 mg
administered every 4 weeks (Q4W). HGT 1410 will be administered intra
- HGT-1410
- Intrathecal Drug Delivery Device
- Mucopolysaccharidosis Type IIIA Disease.
- Pediatric Patients
Sponsors
Shire
Eligibility
Age
2 Years to 11 Years
Inclusion criteria
Inclusion criteria: Patients must meet all of the following criteria to be considered eligible for enrollment:;1. Patient has completed through at least the Week 48 visit of Study HGT-SAN-093. 2. The patient*s parent(s) or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board- (IRB-)/Independent Ethics Committee- (IEC-) approved informed consent form after all relevant aspects of the study have been explained and discussed. Consent of the patient*s parent(s) or legally authorized guardian(s) and the patient*s assent, as relevant, must be obtained.
Exclusion criteria
Exclusion criteria: Patients will be excluded from the study if any of the following criteria are met:;1. The patient, if randomized to treatment in Study HGT-SAN-093, has experienced a decline of more than 20 points in the BSID-III cognitive DQ score between Baseline and the Week 48 visit in Study HGT-SAN-093, AND, upon individual evaluation by the Investigator, has been deemed a treatment failure*. 2. The patient has experienced, in the opinion of the Investigator, a safety or medical issue that contraindicates treatment with HGT-1410, including but not limited to clinically relevant intracranial hypertension, severe infusion-related reactions after treatment with HGT-1410, uncontrollable seizure disorder. 3. The patient has a known hypersensitivity to any of the components of HGT-1410. Patients with documented infusion-related reactions that are clinically manageable (for example, with pre-medication or slowing infusion rate) are not necessarily excluded based on the assessment of the investigator. 4. The patient is enrolled in another clinical study, other than HGT-SAN-093, that involves clinical investigations or use of any investigational product (drug or [intrathecal/spinal] device) within 30 days prior to study enrollment or at any time during the study. 5. The patient has any known or suspected hypersensitivity to anesthesia or is thought to be at an unacceptably high risk for anesthesia due to airway compromise or other conditions. 6. The patient has a condition that is contraindicated as described in the SOPH-APORT ® Mini S IDDD Instructions for Use, including: a.- The patient has had, or may have, an allergic reaction to the materials of construction of the SOPH-A-PORT ® Mini S device b.- The patient*s body size is too small to support the size of the SOPH-A-PORT ® Mini S Access Port, as judged by the Investigator c.- The patient*s drug therapy requires substances known to be incompatible with the materials of construction d.- The patient has a known or suspected local or general infection e.- The patient is at risk of abnormal bleeding due to a medical condition or therapy f.- The patient has one or more spinal abnormalities that could complicate safe implantation or fixation g.- The patient has a functioning CSF shunt device h.- The patient has shown an intolerance to an implanted device 7. The patient is unable to comply with the protocol (eg, is unable to return for safety evaluations, or is otherwise unlikely to complete the study) as determined by the Investigator.;*All treated patients in Study HGT-SAN-093 will have their cognitive development assessed at the Week 48 Visit in Study HGT-SAN-093. If a decline from Baseline of 20 points or less in the BSID-III DQ score is observed, then the patient may proceed into the Study SHP-610-201 without further evaluation. If a decline from Baseline of more than 20 points in DQ score is observed, then an individual evaluation by the Investigator will occur to determine if the patient is a treatment failure. This individual evaluation will take into account the DQ scores, VABS-II score, physical status, and any other information available for that patient at that time. If the Investigator deems the patient to be a treatment failure, then the patient may not enter the Study SHP-610-201.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study Endpoints: Safety evaluations include the assessment of adverse events (AEs), IDDD related issues, laboratory values, anti-rhHNS antibody development, vital signs, physical examination findings, and ECG results | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints of this study are: The change from Baseline in BSID-III or KABC-II age-equivalent, DQ, and developmental delay scores The change from Baseline in adaptive behavioral function domains, assessed by VABS II, using raw scores, age-equivalent scores, and DQ scores The change from Baseline in total cortical grey matter volume, as assessed by MRI The SOPH-A-PORT ® Mini S device will be evaluated using assessments of device implantation, device function, device longevity, and AEs associated with the implant surgery or device. The PK endpoint is to determine the pharmacokinetic behavior of HGT-1410 in serum. The pharmacokinetic behavior of HGT-1410 in CSF will also be determined in patients who received no-treatment in Study HGT-SAN-093. The pharmacodynamic (PD) endpoint is to determine the GAG concentrations in CSF and urine. The health status endpoint is the ITQoL scores at each assessment time and the corresponding change from Baseline. The health economic and outcome research endpoints evaluate key HCUQ variables, such as the number of emergency room visits, caregiver employment status (full-time [FT], part-time [PT], or not working [NW]), and the number of hours of additional paid help needed by caregivers, over the course of the study. | — |
Countries
France, Germany, Italy, Netherlands, Spain, United Kingdom, United States of America
Outcome results
None listed